SANDOZ ALISKIREN TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

ALISKIREN (ALISKIREN FUMARATE)

Предлага се от:

SANDOZ CANADA INCORPORATED

АТС код:

C09XA02

INN (Международно Name):

ALISKIREN

дозиране:

150MG

Лекарствена форма:

TABLET

Композиция:

ALISKIREN (ALISKIREN FUMARATE) 150MG

Начин на приложение:

ORAL

Броя в опаковка:

28

Вид предписание :

Prescription

Терапевтична област:

RENIN INHIBITORS

Каталог на резюме:

Active ingredient group (AIG) number: 0152352001; AHFS:

Статус Оторизация:

CANCELLED PRE MARKET

Дата Оторизация:

2017-12-06

Данни за продукта

_ _
_Sandoz Aliskiren Page 1 of 28_
PRODUCT MONOGRAPH
PR
SANDOZ ALISKIREN
aliskiren (as aliskiren fumarate)
Tablets, 150 and 300 mg
Renin inhibitor
Sandoz Canada Inc.
145 Jules-Léger
Boucherville (QC)
J4B 7K8
Date of Revision: August 31, 2016
Submission Control No: 197205
_ _
_Sandoz Aliskiren Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
3
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
.................................................................................................
8
DRUG INTERACTIONS
................................................................................................
12
DOSAGE AND ADMINISTRATION
...........................................................................
15
OVERDOSAGE
...............................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 16
STORAGE AND STABILITY
.......................................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 19
PART II: SCIENTIFIC INFORMATION
...............................................................................
20
PHARMACEUTICAL INFORMATION
.....................................................................
20
CLINICAL TRIALS
.......................................................................................................
21
DETAILED PHARMACOLOGY
........................................................................